Evidence map›Paper›PMID 26289557›Full record

Trial reportMedical science monitor : international medical journal of experimental and clinical research2015

Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.

Dengqing Zhang, Yuanqing Yao, Jun Qian, Jing Huang

Abstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dengqing ZhangDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Yuanqing YaoDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Jun QianDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Jing HuangDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLevosimendan has been extensively used to treat heart failure (HF) for nearly 10 years, but data on levosimendan used in elderly patients with refractory HF remains limited. This study aimed to investigate the effects of levosimendan on elderly patients with intractable HF. MATERIAL AND

methodsA total of 268 patients with HF (over 70 years, New York Heart Association [NYHA] classification III-IV, LVEF ≤40%, plasma NT-proBNP ≥1000 pg/mL) received conventional anti-HF therapies for 2 weeks. Such therapies include the limiting of salt intake, increasing myocardial contractility (without levosimendan), inducing urine, antagonizing aldosterone, antagonizing myocardial remodeling, and, if necessary, using antibiotics. Our study included 42 patients without symptoms whose improvement was re-evaluated and presented in NYHA class III-IV, LVEF ≤40%, plasma NT-proBNP ≥1000.0 pg/mL, and serum creatinine <110.0 µmol/L. These patients were divided into an experimental groups (n=21, treated with levosimendan) and a control group (n=21, continuously given regular treatment as before). After 1 week, 42 patients were assessed for changes in NYHA classification, LVEF, and NT-proBNP.

resultsNo severe complications related to levosimendan were noted. Compared with the control group, NYHA classification (I-II: 1 versus 21, III-IV: 20 versus 0, P<0.05) and LVEF (30.62±6.19% versus 45.83±5.06%, P<0.05) were increased, and plasma NT-proBNP was reduced (458.35±193.16 pg/mL versus 2921.52±1395.97 pg/mL, P<0.05) in the experimental group.

conclusionsOur study showed levosimendan significantly and safely improved clinical outcomes of refractory heart failure in elderly patients.

Indexed as

AgedAged, 80 and overAnti-Arrhythmia AgentsAsian PeopleChinaCreatinineFemaleHeart FailureHumansHydrazonesMaleNatriuretic Peptide, BrainPeptide FragmentsProspective StudiesPyridazinesSimendanAnti-Arrhythmia AgentsCreatinineHydrazonesNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)PyridazinesSimendan

Identifiers

PMID26289557
PMCPMC4548701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.